- Home
- ACAD
as 12-03-2024 12:30pm EST
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.6B | IPO Year: | 2004 |
| Target Price: | $26.44 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.15 - $32.59 | Next Earning Date: | 11-06-2024 |
| Revenue: | $929,236,000 | Revenue Growth: | 47.06% |
| Revenue Growth (this year): | 37.34% | Revenue Growth (next year): | 7.25% |
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Nov 17 '24 | Sell | $16.81 | 4,073 | $68,467.13 | 19,863 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Nov 17 '24 | Sell | $16.81 | 10,259 | $172,453.79 | 53,302 | |
| Teehan Brendan | ACAD | EVP, COO, HEAD OF COMMERCIAL | Nov 17 '24 | Sell | $16.81 | 10,329 | $173,630.49 | 62,105 |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
Zacks
4 hours ago
Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options
Zacks
6 days ago
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
Pharmaceutical Technology
6 days ago
Acadia signs agreement with Saniona to commercialise SAN711
MT Newswires
7 days ago
Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront
Business Wire
7 days ago
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
Business Wire
12 days ago
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Business Wire
18 days ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
20 days ago
High Growth Tech Stocks to Watch in November 2024
Compare ACAD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.